ResearcherUniversity of Wisconsin–MadisonNo recent work listed

Andrew M Baschnagel

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper

Papers 2

The significance of Trk receptors in pancreatic cancer. Co-author DOI 10.1177/1010428317692256 ↗
Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. Co-author DOI 10.1016/j.ijrobp.2012.01.008 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

John M. Robertson · 2 shared papers, 2012–2017 · strength 0.09
- Paper The significance of Trk receptors in pancreatic cancer. DOI 10.1177/1010428317692256 ↗
- Paper Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. DOI 10.1016/j.ijrobp.2012.01.008 ↗
Matthew D. Johnson · 1 shared paper, 2017 · strength 0.06
- Paper The significance of Trk receptors in pancreatic cancer. DOI 10.1177/1010428317692256 ↗
George David Wilson · 1 shared paper, 2017 · strength 0.06
- Paper The significance of Trk receptors in pancreatic cancer. DOI 10.1177/1010428317692256 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.